Skip to main content
S&P 5007,807.24-0.06%DOW51,850.55+0.38%NASDAQ27,245.90-0.44%GOLD$4,195.90-0.48%OIL$93.16+1.43%
Delayed
Smart Investors Daily
SID Premium
Sumitomo Pharma Co., Ltd. logo

OTC · SMDPY

Sumitomo Pharma Co., Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$10.33

Up+$0.00 (+0.00%)

Updated Oct 12, 2026, 8:55 PM

SID Score

6.0/10

Composite research score

Smart Money

46/100

Neutral

Market cap
4.55B
P/E ratio
5.76
Dividend yield
0.00%
52-week range
— – —
Volume
1K
Avg. volume
17

Price performance · SMDPY

SMDPY price history

1M range · 0 trading sessions · Daily adjusted prices

SMDPY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SMDPY news

The latest Smart Investors Daily articles mentioning SMDPY.

Stock researchCompany · Overview

SMDPY research

Overview

Company profile and research snapshot.

Company profile

SUMITOMO PHARMA CO U/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.40
Implied upside
—
Analysts
11
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight

Recently published Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, emerging schizophrenia drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Yahoo · Sep 15, 2026

Slate Medicines Names Kenneth Koblan as Chief Scientific Officer

By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations. Dr. Koblan is a biopharmaceutical R&D leader with more than 30 years […] The post Slate Medicines Names Kenneth Koblan as Chief Scientific Officer appeared first on ExecEdge.

Yahoo · Sep 10, 2026

2026 Assessment of the Nuvisertib Market: Sales Forecasts, Clinical Differentiation, Competitive Threats, and Commercial Opportunities Through 2034

Nuvisertib targets unmet needs in relapsed/refractory myelofibrosis with differentiated, potentially disease-modifying activity. Combination therapy, expansion into other cancers and expedited regulatory pathways offer additional opportunities.Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Nuvisertib Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Nuvisertib (TP-3654) is an investigational, orally administered, highly selective PIM1 kinase i

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By